Powered by

Cybrexa Therapeutics to Present Preclinical Data for its Tumor-Selective Technology Platform at the 30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

Nov 05, 2018 - GlobeNewswire

NEW HAVEN, Conn., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its tumor-selective technology platform, today announced that the company will present preclinical data at the 30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium to be held November 13 - 16, 2018 in Dublin, Ireland. The preclinical data that will be presented includes the successful conjugation of BMN673 (Talazoparib, a PAR...